
    
      DOV 21,947 is an investigational drug that is being developed for the treatment of
      depression. The purpose of this study is to evaluate the safety and effectiveness of a
      flexible dosing schedule of DOV 21,947 (25 mg twice daily for two weeks, then 50 mg twice
      daily for four weeks as compared to placebo) in the treatment of major depressive disorder.
      Information about any side effects that may occur will also be collected.

      The efficacy evaluation will be based on the change in the total MADRS and HAMD-17 scores
      from randomization to week 9 .The secondary objective is to determine if DOV 21,947 improves
      the quality of life for patients with MDD as compared to placebo
    
  